Drapkin R, Bjornsson S, Naeher C, Higby D, Caracandas J, Wallens W T, Kuberka N, Suh K, Siddiqi N, Henderson E S
Cancer Treat Rep. 1980;64(12):1367-9.
Forty previously untreated patients with stage III non-small cell bronchogenic carcinoma were treated with doxorubicin (Adriamycin) at a dose of 60 mg/m2 iv on Day 1 and cisplatin (cis-diamminedichloroplatinum[II]) at a dose of 60-80 mg/m2 iv on Day 1, every 4 weeks. Each patient was randomized to receive iv Corynebacterium parvum either on Day 1 or on Day 14 of each 4-week cycle. There were no complete responses and only seven of 40 (17.5%) patients achieved a partial response, with an overall median survival of 23 weeks. Those patients with stable disease survived longest. There was no difference in median survival among those patients receiving C. parvum on Day 1 (25 weeks) and among those receiving C. parvum on Day 14 (17 weeks).
40例先前未经治疗的Ⅲ期非小细胞支气管源性癌患者接受了如下治疗：阿霉素（阿霉素）在第1天静脉注射，剂量为60mg/m²，顺铂（顺二氨二氯铂[II]）在第1天静脉注射，剂量为60-80mg/m²，每4周重复一次。每位患者被随机分配在每4周周期的第1天或第14天静脉注射短小棒状杆菌。没有完全缓解，40例患者中只有7例（17.5%）获得部分缓解，总中位生存期为23周。病情稳定的患者存活时间最长。在第1天接受短小棒状杆菌治疗的患者（25周）和在第14天接受短小棒状杆菌治疗的患者（17周）之间，中位生存期没有差异。
